Interleukin-1β modulation using a genetically engineered antibody prevents adverse cardiac remodelling following acute myocardial infarction in the mouse

European Journal of Heart Failure

Volumn 12, Issue 4, 2010, Pages 319-322

  Abbate, Antonio ^a   Van Tassell, Benjamin W ^a   Seropian, Ignacio M ^a   Toldo, Stefano ^a   Robati, Roshanak ^a   Varma, Amit ^a   Salloum, Fadi N ^a   Smithson, Lisa ^a   Dinarello, Charles A ^b  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G1 ANTIBODY; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA ANTIBODY; UNCLASSIFIED DRUG; XMA 052 MG 1K; ANTIBODY; ANTIRHEUMATIC AGENT; CYTOKINE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 2 RECEPTOR;

ACUTE HEART INFARCTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY AFFINITY; ANTIBODY ENGINEERING; ARTICLE; CARDIAC REMODELLING; CONTROLLED STUDY; DISEASE MODEL; DRUG DOSE COMPARISON; DRUG EFFECT; GENETIC ENGINEERING; HEART DISEASE; HEART INFARCTION SIZE; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE FILLING; HEART SIZE; IMMUNOMODULATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME; ANALYSIS OF VARIANCE; ANIMAL; DISEASE COURSE; ECHOGRAPHY; HEART FAILURE; HEART INFARCTION; HEART VENTRICLE REMODELING; IMMUNOLOGY; INSTITUTE FOR CANCER RESEARCH MOUSE; PATHOPHYSIOLOGY;

ANALYSIS OF VARIANCE; ANIMALS; ANTIBODIES; ANTIRHEUMATIC AGENTS; CYTOKINES; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GENETIC ENGINEERING; HEART FAILURE; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1BETA; MALE; MICE; MICE, INBRED ICR; MYOCARDIAL INFARCTION; RECEPTORS, INTERLEUKIN-2; VENTRICULAR REMODELING;

EID: 77950279969     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1093/eurjhf/hfq017     Document Type: Article

References (14)

1. Frangogiannis N. The immune system and cardiac repair. Pharm Res 2008;58: 88-111.
2. Dinarello C. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 2009;27:519-550.
3. Bujak M, Dobaczewski M, Chatila K, Mendoza L, Li Reddy A, Frangogiannis N. Interleukin-1 receptor type I signaling critically regulates infarct healing and cardiac remodeling. Am J Pathol 2008;173:57-67.
4. Abbate A, Salloum F, Vecile E, Das A, Hoke N, Straino S, Biondi-Zoccai GGL, Houser J, Qureshi I, Ownby E, Gustini E, Biasucci L, Severino A, Capogrossi M, Vetrovec G, Crea F, Baldi A, Kukreja R, Dobrina A. Anakinra, a recombinant human interleukin-1 receptor antagonist, inhibits apoptosis in experimental acute myocardial infarction. Circulation 2008;117:2670-2683.
5. Crossman D, Morton A, Gunn J, Greenwood J, Hall A, Fox K, Lucking A, Flather M, Lees B, Foley C. Investigation of the effect of Interleukin-1 receptor antagonist (IL-1ra) on markers of inflammation in non-ST elevation acute coronary syndromes (The MRC-ILA-HEART Study). Trials 2008;9:8-14.
6. Abbate A, Kontos MC, Grizzard JD, Biondi-Zoccai GGL, Van Tassell BW, Robati R, Roach LM, Arena RA, Roberts CF, Varma A, Gelwix CC, Salloum FN, Hastillo A, Dinarello CA, Voetrovec GW. Interleukin-1 Blockade with Anakinra to Prevent Adverse Cardiac Remodeling Following Acute Myocar-dial Infarction. Am J Cardiol 2010; in press.
7. http://www.xoma.com/pipeline/xoma-052/ (last accessed on 26 September 2009).
8. Hwang MW, Matsumori A, Furukawa Y, Ono K, Okada M, Iwasaki A, Hara M, Miyamoto T, Touma M, Sasayama S. Neutralization of interleukin-1 in the acute phase of myocardial infarction promotes the progression of left ventricular remodeling. J Am Coll Cardiol 2001;38:1546-1553.
9. Gardin J, Adams D, Douglas P, Feigenbaum H, Forst D, Fraser A, Grayburn P, Katz A, Keller A, Kerber R, Khandheria B, Klein A, Lang R, Pierard L, Quinones M, Schnittger I. Recommendations for a standardized report for adult transthoracic echocardiography: a report from the American Society of Echocardiography's Nomenclature and Standards Committee and Task Force for a Standardized Echocardiography Report. J Am Soc Echocardiography 2002; 15:275-290.
10. Van Tassell BW, Varma A, Salloum FN, Das A, Seropian IM, Toldo S, Smithson L, Hoke NN, Chau VQ, Robati R, Abbate A. Interleukin-1 Trap attenuates cardiac remodeling after experimental acute myocardial infarction in mice. J Cardiovasc Pharmacol 2009; Published online ahead of print 13 November.
11. Kaminski MS, Kitamura K, Maloney DG, Campbell MJ, Levy R. Importance of antibody isotype in monoclonal anti-idiotype therapy of a murine B-cell lymphoma. A study of hybridoma class switch variants. J Immunol 1986;136:1123-1131.
12. Mann DL. Targeted anticytokine therapy and the failing heart. Am J Cardiol 2005; 95 (Suppl):9C-16C.
13. Roell MK, White M, Issafras H, Michelson K, Vanegas S, Gross L, Lee S, Mirza A, Hunter J, Corbin J, Kantak S, Doberstein S. XOMA 052, a monoclonal antibody that regulates interleukin-1 beta (IL-1beta) activity: an example of a new class of regulatory antibody drugs that may confer a unique advantage in the treatment of type 2 diabetes mellitus. Diabetologia 2009;52 (Suppl. I):S-154.
14. Honsho S, Nishikawa S, Amano K, Zen K, Adachi Y, Kishita E, Matsui A, Katsume A, Yamaguchi S, Nishikawa K, Isoda K, Riches DWH, Matoba S, Okigaki M, Matsubara H. Pressure-mediated hypertrophy and mechanical stretch induces IL-1 release and subsequent IGF-1 generation to maintain compensative hypertrophy by affecting Akt and JNK pathways. Circ Res 2009;105:1149-1158.